Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

SVLSF VI, LLC

2. Date of Event Requiring Statement (MM/DD/YYYY) 9/27/2019

3. Issuer Name and Ticker or Trading Symbol

MISONIX INC [MSON]

(Last) (First) (Middle)

ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director ___X___ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

BOSTON, MA 02108

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock ⁽¹⁾	1639826 ⁽²⁾	I	By: SV Life Sciences Fund VI, L.P. ⁽²⁾⁽⁴⁾
Common Stock ⁽¹⁾	56143 ⁽³⁾	I	By: SV Life Sciences Fund VI Strategic Partners, L.P. ⁽³⁾⁽⁴⁾

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:
(1)	Acquired pursuant to the Agreement and Plan of Merger between Misonix, Inc., New Misonix, Inc., Motor Reincorp. Sub One, Inc., Surge Sub Two, LLC, Solsys Medical, LLC ("Solsys"), and Greg Madden solely in his capacity as representative, in exchange for 27,116,608 Series E Preferred Units of Solsys. The Merger Agreement placed a value on the issuer's common stock of $18.5479, which reflects the 10-day VWAP for the issuer's common stock as of three business days prior to the effective date of the merger.
(2)	These shares are owned directly by SV Life Sciences Fund VI, L.P. ("SVLS VI LP"). 199,617 of the shares issued to SVLS VI LP are being held in escrow and are subject to forfeiture during the 15 month-period following the merger to satisfy any post-closing purchase price adjustments and indemnification claims. SV Life Sciences Fund VI (GP), L.P. ("SVLS VI GP"), the general partner of SVLS VI LP, may be deemed to share voting and dispositive power over the shares held by SVLS VI LP. SVLS VI GP disclaims beneficial ownership of shares held by SVLS VI LP except to the extent of any pecuniary interests therein.
(3)	These shares are owned directly by SV Life Sciences Fund VI Strategic Partners, L.P. ("Strategic Partners"). 6,834 of the shares issued to Strategic Partners are being held in escrow and are subject to forfeiture during the 15 month-period following the merger to satisfy any post-closing purchase price adjustments and indemnification claims. SVLS VI GP, the general partner of Strategic Partners, may be deemed to share voting and dispositive power over the shares held by Strategic Partners. SVLS VI GP disclaims beneficial ownership of shares held by Strategic Partners except to the extent of any pecuniary interests therein.
(4)	SVLS VI LP and Strategic Partners (each a "Fund," or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
SVLSF VI, LLC ONE BOSTON PLACE 201 WASHINGTON STREET, SUITE 3900 BOSTON, MA 02108		X
SV Life Sciences Fund VI, L.P. C/O SV LIFE SCIENCES ADVISERS LLC ONE BOSTON PLACE, SUITE 3900 BOSTON, MA 02108		X
SV Life Sciences Fund VI (GP), L.P. ONE BOSTON PLACE 201 WASHINGTON STREET, SUITE 3900 BOSTON, MA 02108		X
SV Life Sciences Fund VI Strategic Partners, L.P. C/O SV LIFE SCIENCES ADVISERS, LLC ONE BOSTON PLACE, SUITE 3900 BOSTON, MA 02108		X

Signatures
SV Life Sciences Fund VI, L.P., By: SV Life Sciences Fund VI (GP), L.P., its sole general partner, By: SVLSF VI, LLC, its sole general partner, By: Brent M. Faduski, Officer, /s/ Brent M. Faduski		10/7/2019
^**Signature of Reporting Person		Date
SV Life Sciences Fund VI Strategic Partners, L.P., By: SV Life Sciences Fund VI (GP), L.P., its sole general partner, By: SVLSF VI, LLC, its sole general partner, By: Brent M. Faduski, Officer, /s/ Brent M. Faduski		10/7/2019
^**Signature of Reporting Person		Date
SV Life Sciences Fund VI (GP), L.P., By: SVLSF VI, LLC, its sole general partner, By: Brent M. Faduski, Officer, /s/ Brent M. Faduski		10/7/2019
^**Signature of Reporting Person		Date
SVLSF VI, LLC, By: Brent M. Faduski, Officer, /s/ Brent M. Faduski		10/7/2019
^**Signature of Reporting Person		Date